Floatz logo

HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3

Recurrent T Acute Lymphoblastic Leukemia

City of Hope Medical Centermonoclonal_antibodyPhase 1Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

80 Active assets in the Recurrent T Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Children's Oncology Group
Phase 3BB
PEGASPARGASE
Children's Oncology Group
Phase 3BB
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT)
University of Washington
Phase 3BB
MERCAPTOPURINE ANHYDROUS
SWOG Cancer Research Network
Phase 3BB
Daunorubicin
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

HUMANIZED, DUAL-AFFINITY RE-TARGETING, OR (DART), MOLECULE THAT RECOGNIZES BOTH CD123 AND CD3 is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
54 / 100
View asset →
chronic myeloid leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →
hairy cell leukemiaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →